Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...